Scarica l'app Stockscreener
82.24
3.10%
-2.63
Dopo l'orario di chiusura:
82.14
-0.10
-0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Is Cytokinetics (CYTK) A Bargain On Myqorzo Approval Or Already Fully Priced? - Yahoo Finance
How Myqorzo’s Commercial Launch At Cytokinetics (CYTK) Has Changed Its Investment Story - Yahoo Finance
Price to sales forward of Cytokinetics, Incorporated – NASDAQ:CYTK - TradingView
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure? - Yahoo Finance
Cytokinetics, Incorporated Stock 12‑Month Price Target Raised to $108.47, Implies 26% Upside - TradingView
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
FMR LLC holds 5.25M shares of Cytokinetics (NASDAQ: CYTK) in 13G/A - Stock Titan
CYTOKINETICS (CYTK) EVP exercises options, sells 3,500 shares in open market - Stock Titan
CYTK (NASDAQ: CYTK) files Form 144 for 24,500-share option exercise sale - Stock Titan
Cytokinetics’ SWOT analysis: cardiovascular stock eyes growth with Myqorzo By Investing.com - Investing.com Nigeria
Cytokinetics’ SWOT analysis: cardiovascular stock eyes growth with Myqorzo - Investing.com
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Cuts Target Price to $117 - Moomoo
CYTK Maintained by RBC Capital -- Price Target Lowered to $117 - GuruFocus
RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating - marketscreener.com
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026 - The Manila Times
Cytokinetics lands three ESC 2026 presentations on heart drug data - Stock Titan
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of ... - Caledonian Record
CYTKCytokinetics Inc Latest SEC Filings - Finviz
Cytokinetics CEO Robert Blum sells $636,900 in stock - Investing.com UK
Insider Sell Alert: EVP, Chief Financial Officer Sung Lee Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
CYTK News | CYTOKINETICS INC (NASDAQ:CYTK) - ChartMill
Cytokinetics EVP Andrew Callos sells $1.29 million in shares - Investing.com UK
Cytokinetics CEO Robert Blum sells $636,900 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $1.29 million in shares By Investing.com - Investing.com South Africa
Cytokinetics Insider Sold Shares Worth $1,287,000, According to a Recent SEC Filing - marketscreener.com
Cytokinetics (NASDAQ: CYTK) CEO trims stake with 7,500-share sale - Stock Titan
Cytokinetics (NASDAQ: CYTK) EVP exercises options, sells 15,000 shares at $85.80 - Stock Titan
CYTOKINETICS (NASDAQ: CYTK) CFO exercises options, sells 1,112 shares at $87.79 - Stock Titan
Form 144 CYTOKINETICS For: 1 July By Investing.com - Investing.com UK
CYTK insider Robert Blum notifies planned sale of 44,990 shares (CYTK) - Stock Titan
Cytokinetics Inc stock hits 52-week high at $88.00 - Investing.com
Cytokinetics Inc stock hits 52-week high at $88.00 By Investing.com - Investing.com India
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Cytokinetics (CYTK) - The Globe and Mail
Cytokinetics CFO Lee Sung sells $3.18m in company stock By Investing.com - Investing.com South Africa
Cytokinetics CFO Lee Sung sells $3.18m in company stock - Investing.com
Form 144 CYTOKINETICS For: 29 June By Investing.com - Investing.com South Africa
Form 4 Cytokinetics Inc For: 29 June By Investing.com - Investing.com South Africa
Cytokinetics(CYTK.US) Officer Sells US$3.19 Million in Common Stock - Moomoo
Cytokinetics (CYTK) CFO sells 38,730 shares at $82.30 after exercising options - Stock Titan
Cytokinetics CFO Lee Sung sells $266,390 of company stock By Investing.com - Investing.com South Africa
Cytokinetics CFO Lee Sung sells $266,390 of company stock - Investing.com
Cytokinetics (NASDAQ: CYTK) CFO trades shares after option exercises - Stock Titan
5.60%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):